The expression of AEG-1、HER2 in gastric carcinoma and its clinical significance

doi:10.3877/cma.j.issn.1674-3946.2020.05.017

Abstract

Abstract:

Objective

To investigate the expression of AEG-1、HER2 in gastric cancer tissue and its relationship with clinical-pathological features.

Methods

The expression of AEG-1、HER2 in 96 cases of patients with gastric cancer from January 2013 to January 2018 were detected by immunohistochemical method. The paracancerous tissues were selected randomly from 20 cases as the control group. We observed the association of AEG-1、HER2 in gastric carcinoma and its relationship with clinical pathological features Statistical procedures were done using SPSS version 16.0. Comparison between qualitative data was performed using Chi-square test, Linear trend test, Spearman correlation analysis or Kaplan-Meier survival curves according to different analytical purposes respectively. P<0.05 was considered as statistically significant.

Results

The positive expression of AEG-1 in gastric cancer (76.0%) was significantly higher than that in adjacent normal gastric tissue(0%). The positive expression of AEG-1 in gastric cancer was closely correlated with differentiation degree、clinical TNM stages and lymph node metastasis (P<0.05). The positive expression of HER2 in gastric cancer (41.7%) was significantly higher than that in adjacent normal gastric tissue(0%). The positive expression of HER2 in gastric cancer was closely correlated with differentiation degree、invasion depth、clinical TNM stages and lymph node metastasis (P<0.05). Spearman correlation analysis showed that there was a line relationship between AEG-1 and HER2 in gastric cancer (r=0.276, P=0.007). Kaplan-Meier survival curves showed the survival time of patients with the dual-negative expression of AEG-1 and HER2 (Mean survival time: 48.3 months) had significantly longer than that with the dual-positive expression of AEG-1 and HER2 (Mean survival time: 31.1 months) (P<0.05).

Conclusion

There may be AEG-1、HER2 signaling pathway in gastric carcinoma. Detecting the expression of AEG-1、HER2 in gastric cancer tissues could judge the occurrence、development、invasion and metastasis of gastric carcinoma and evaluate the prognosis of gastric cancer.

Key words: Stomach neoplasms, Genes, erbB-2, AEG-1, Pathological

Yong Huang, Jing Wang, Guangjian Bao, Zengjun Lun, Peng Chu, Liang Zhi. The expression of AEG-1、HER2 in gastric carcinoma and its clinical significance[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2020, 14(05): 487-490.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2020.05.017

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2020/V14/I05/487

Figures/Tables 8

References 15

[1]	郑潇豪，解亦斌．中国晚期胃癌的诊疗现状[J]．癌症进展，2019，17(1):13-19,48.
[2]	熊骋峰，吕云霞．AEG-1与头颈肿瘤的研究进展[J]．江西医药，2018, 53(1): 87-89.
[3]	唐焕，尹晓玲，张献全．HER2与胃癌预后的研究进展[J]. 现代医药卫生，2018，34(10): 1522-1525.
[4]	徐国帅，蔡相军，陈江波，等．AEG-1和CHD5在胃癌中的表达及其临床意义[J]．中国医科大学学报，2018, 47(9): 797-802.
[5]	刘凯军，李勇，王文韬．胃癌组织中AEG-1的表达及与临床病理特征的关系研究[J]．河北医药，2012，34(5):653-655.
[6]	Wu SJ，Yang L，Wu DD，et al. AEG-1 induces gastric cancer metastasis by upregulation of eIF4E expression [J]. J Cell Mol Med, 2017, 21(12):3481-3493.
[7]	《胃癌HER检测指南(2016版) 》专家组．胃癌HER2检测指南(2016版)[J]．中华病理学杂志，2016，45(8):528-532.
[8]	王瑞珍，郭卫东. AEG-1在恶性肿瘤中作用机制的研究进展[J]．世界最新医学信息文摘，2017, 17(86): 55-56.
[9]	黄仕灵，谢乐，秦原森．AEG-1对大肠癌进展的影响[J]．中国微生态学杂志，2018，30(10): 1150-1154.
[10]	李英红，刘珺珺，宁晓明，等. AEG-1基因促进乳腺癌细胞株MCF-7转移[J]. 实用肿瘤学杂志，2017, 31(4): 299-304.
[11]	中国临床肿瘤学会抗肿瘤药物安全管理专家委员会，中国抗癌协会胃癌专业委员会，中国抗癌协会肿瘤病理专业委员会. HER2阳性晚期胃癌分子靶向治疗的中国专家共识(2016版) [J]．临床肿瘤学杂志，2016，21(9):831-839.
[12]	刘晓伟，张宏. HER2蛋白在胃癌组织中的表达及其临床研究[J]. 内蒙古医科大学学报，2018，40(4) :412-414.
[13]	朱琳，顾春燕，陈丽燕，等. HER2在胃癌原发灶和淋巴结转移灶中表达的对比研究[J]. 南通大学学报(医学版)，2018，38(1):20-23.
[14]	Wang Y, He L, Cheng Y. An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis[J]. Clin Transl Oncol, 2018, 20(2):212-220.
[15]	Zhang X, Zhang N, Zhang MX. Astrocyte elevated gene-1 induces breast cancer proliferation and invasion through upregulating HER2/neu expression[J]. Chin Med J (Engl)，2011，124 (21): 3546-3550.

病理类型	例	AEG-1表达情况			HER2表达情况
病理类型	例	阳性	χ²值	P值	阳性	χ²值	P值
胃癌组织	96	73(76.0)	37.832	0.000	40(41.7)	10.94	0.000
癌旁组织	20	0(0)	37.832	0.000	0(0)	10.94	0.000

病理类型	例	AEG-1表达情况			HER2表达情况
病理类型	例	阳性	χ²值	P值	阳性	χ²值	P值
胃癌组织	96	73(76.0)	37.832	0.000	40(41.7)	10.94	0.000
癌旁组织	20	0(0)	37.832	0.000	0(0)	10.94	0.000

临床特征		例	AEG-1表达		HER2表达
临床特征		例	阳性(%)	P值	阳性(%)	P值
年龄(岁)		?	?	?	?	?
?	<60	44	33(75.0)	0.826	17(38.6)	0.580
?	≥60	52	40(76.9)	0.826	23(44.2)	0.580
性别		?	?	?	?	?
?	男	53	38(71.7)	0.268	21(39.6)	0.652
?	女	43	35(81.4)	0.268	19(44.1)	0.652
肿瘤大小(cm)		?	?	?	?	?
?	<5	50	37(74.0)	0.625	18(36.0)	0.24
?	≥5	46	36(78.3)	0.625	22(47.8)	0.24
肿瘤部位		?	?	?	?	?
?	贲门、胃底	28	20(71.4)	0.742	12(42.8)	0.908
?	胃体	20	15(75.0)		9(45.0)
?	胃窦	48	38(79.2)		19(39.5)
分化程度(级)		?	?	?	?	?
?	高-中分化	40	26(65.0)	0.032	22(55.0)	0.025
?	未-低分化	56	47(83.9)	0.032	18(32.1)	0.025
浸润深度		?	?	?	?	?
?	黏膜固有层及	?	?	?	?	?
?	黏膜下层组	9	5(55.6)	?	1(11.1)	?
?	固有肌层及	?	?	?	?	?
?	浆膜下层组	20	15(75.0)	0.338	5(25.0)	0.012
?	侵犯浆膜层组	67	53(79.1)	?	34(50.7)	?
Lauren分型		?	?	?	?	?
?	肠型组	24	18(75.0)	0.944	12(50.0)	0.619
?	弥漫型组	53	40(75.5)		21(39.6)
?	混合型组	19	15(78.9)		7(36.8)
临床分期		?	?	?	?	?
?	Ⅰ～Ⅱ	35	22(62.8)	0.022	10(28.5)	0.049
?	Ⅲ	61	51(83.61)	0.022	30(49.1)	0.049
淋巴结转移		?	?	?	?	?
?	有	68	56(82.3)	0.024	33(48.5)	0.034
?	无	28	17(60.7)	0.024	7(25.0)	0.034

临床特征		例	AEG-1表达		HER2表达
临床特征		例	阳性(%)	P值	阳性(%)	P值
年龄(岁)		?	?	?	?	?
?	<60	44	33(75.0)	0.826	17(38.6)	0.580
?	≥60	52	40(76.9)	0.826	23(44.2)	0.580
性别		?	?	?	?	?
?	男	53	38(71.7)	0.268	21(39.6)	0.652
?	女	43	35(81.4)	0.268	19(44.1)	0.652
肿瘤大小(cm)		?	?	?	?	?
?	<5	50	37(74.0)	0.625	18(36.0)	0.24
?	≥5	46	36(78.3)	0.625	22(47.8)	0.24
肿瘤部位		?	?	?	?	?
?	贲门、胃底	28	20(71.4)	0.742	12(42.8)	0.908
?	胃体	20	15(75.0)		9(45.0)
?	胃窦	48	38(79.2)		19(39.5)
分化程度(级)		?	?	?	?	?
?	高-中分化	40	26(65.0)	0.032	22(55.0)	0.025
?	未-低分化	56	47(83.9)	0.032	18(32.1)	0.025
浸润深度		?	?	?	?	?
?	黏膜固有层及	?	?	?	?	?
?	黏膜下层组	9	5(55.6)	?	1(11.1)	?
?	固有肌层及	?	?	?	?	?
?	浆膜下层组	20	15(75.0)	0.338	5(25.0)	0.012
?	侵犯浆膜层组	67	53(79.1)	?	34(50.7)	?
Lauren分型		?	?	?	?	?
?	肠型组	24	18(75.0)	0.944	12(50.0)	0.619
?	弥漫型组	53	40(75.5)		21(39.6)
?	混合型组	19	15(78.9)		7(36.8)
临床分期		?	?	?	?	?
?	Ⅰ～Ⅱ	35	22(62.8)	0.022	10(28.5)	0.049
?	Ⅲ	61	51(83.61)	0.022	30(49.1)	0.049
淋巴结转移		?	?	?	?	?
?	有	68	56(82.3)	0.024	33(48.5)	0.034
?	无	28	17(60.7)	0.024	7(25.0)	0.034

AEG-1表达	HER2表达		例数
AEG-1表达	阳性	阴性	例数
阳性	36	37	73
阴性	4	19	23
合计	40	56	96

Please choose a citation manager

Content to export